Rysanso
CompoundThe proposed brand name for Resilient Pharmaceuticals' (formerly Lykos, before that MAPS PBC) resubmitted MDMA-assisted therapy candidate for PTSD, revealed via a trademark filing rather than a formal announcement.
Example: A brand name filed this far ahead of any approval is its own signal — it means the company is positioning for a market launch, not just another regulatory round. Rysanso is still investigational; MDMA remains a Schedule I substance and no MDMA-assisted therapy has been FDA-approved.
What is Rysanso?
The proposed brand name for Resilient Pharmaceuticals' (formerly Lykos, before that MAPS PBC) resubmitted MDMA-assisted therapy candidate for PTSD, revealed via a trademark filing rather than a formal announcement.
Is Rysanso FDA-approved?
No — it's still investigational. MDMA remains a Schedule I substance, and no MDMA-assisted therapy has been FDA-approved.
Why does a brand-name filing matter before approval?
It signals the company is positioning for a market launch, not just another regulatory round — filing a brand name this far ahead of any approval is its own signal. See our coverage.